Home  /  Covid-19   /  RCR01-RCR15 Covid-19 Rolling Collaborative Review – Third round of reviews now available

RCR01-RCR15 Covid-19 Rolling Collaborative Review – Third round of reviews now available

As part of its response to the Covid-19 pandemic, EUnetHTA is working to output ‘Rolling Collaborative Reviews (RCR)’. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic health technologies relevant to the management of the current pandemic.

EUnetHTA is pleased to announce that the third round of these monthly updated Covid-19 Rolling Collaborative Reviews (RCR) is now available.

Please access the reviews, together with the project description and planning, here:

RCR01-RCRXX – Project Description and Planning

RCR01: Convalescent Plasma Treatment

RCR02: Lopinavir + Ritonavir (Kaletra©)

RCR03: Tocilizumab (RoActemra©)

RCR04: Camostat (Foipan©)

RCR05: Nafamostat (Futhan©)

RCR06: Solnatide

RCR07: Anakinra

RCR08: Dexamethasone – Dexamethasone has been deleted from the RCR list according to our stopping criteria. The compound will be assessed in a EUnetHTA Rapid Collaborative Review, under the project description ‘PTRCR18 – Dexamethasone for the treatment of COVID-19’, to be accessible here.

RCR09: APN01 (rhACE2)

RCR10: Darunavir (Prezista©)

RCR11: Favipiravir (Avigan©)

RCR12: Sarilumab (Kevzara©)

RCR13: Interferon beta 1a

RCR14: Gimsilumab*

RCR15: Canakinumab*

*From October 2020, the update of the literature search for Gimsilumab / Canakinumab will be done on a bi-monthly basis. In case new evidence is identified in the bi-monthly literature search, this RCR will be updated and my be put back into the monthly process.